Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
“Patients with blood cancers and those undergoing transplantation are at
much higher risk for opportunistic fungal infections, often the cause of
significant morbidity and mortality,” said
CD101 data accepted for presentation at this year’s ASH Annual Meeting comprise the following:
- Two poster presentations evaluating the efficacy of CD101 for the treatment and prevention of invasive fungal infections due to the pathogens, Candida, Aspergillus and Pneumocystis.
- A poster presentation summarizing results from the successful Phase 1 clinical trial of CD101 IV, demonstrating the safety and pharmacokinetics of single and multiple weekly dosing regimens.
Approximately 97,000 Americans die from hospital-related fungal infections each year and 90 percent of these infections are caused by two common fungi, Candida and Aspergillus. Systemic fungal infections typically affect patients whose immune systems have been compromised, such as patients undergoing organ or bone marrow transplantation or chemotherapy including patients with hematologic malignancies. Pneumocystis is another serious fungal infection that commonly afflicts people with weakened immune systems.
“Invasive fungal infections remain a significant threat in patients with
hematological cancer and in transplant recipients. Although significant
progress has been made in diagnostics and the introduction of new
agents, significant challenges remain,” said Dimitrios P. Kontoyiannis,
M.D., of
Details for the Cidara ASH 2016 presentations are as follows:
- Pharmacokinetics, Safety, and Target Attainment of Single and Multiple Doses of CD101 IV; T Sandison, et. al. #2197
- Efficacy of CD101, a Novel Echinocandin, in Mouse Models of Aspergillosis and Azole-Resistant Disseminated Candidiasis; V. Ong, et. al. #3400
- Efficacy of CD101, a Novel Echinocandin, in Prevention of Pneumocystis Pneumonia (PCP): Thwarting the Biphasic Life Cycle of Pneumocystis; M. Cushion, et. al. #3396
Abstracts can be found at www.hematology.org and copies of these poster presentations will also be available on the Cidara website following the meeting: http://www.Cidara.com/
About
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101, through Phase 2
studies in two indications and developing CD201, its bispecific
antimicrobial immunotherapy, for the treatment of multi-drug resistant
bacterial infections. CD101 IV has enhanced potency and is the only
once-weekly therapy intended for the treatment and prevention of
life-threatening invasive fungal infections. CD101 topical is the first
and only agent of its class being studied for the treatment and
prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal
infection. CD201 is the first drug candidate selected from Cidara’s
novel Cloudbreak™ platform, the first immunotherapy discovery platform
designed specifically to create compounds that direct a patient's immune
cells to attack and eliminate bacterial, fungal or viral pathogens.
Cidara is headquartered in
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101, and its
potential to treat infections, including infections associated with
hematologic malignancies and transplantation. Risks that contribute to
the uncertain nature of the forward-looking statements include: the
success and timing of Cidara’s preclinical studies and clinical trials;
regulatory developments in
View source version on businesswire.com: http://www.businesswire.com/news/home/20161128005107/en/
Source:
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com